Drugs / CAR19T2 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05613348 | Dec 2022 → Dec 2025 | B-cell acute lymphoblastic leukemia | Zhujiang Hospital | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR19T2 T cells | “new third-generation autologous T cells (CAR19T2 T cells) genetically modified with humanized anti-CD19 construct incorporating CD28 and Toll-like receptor 2 (TLR2)...” NCT05613348 ↗ |
| Action | Deplete | “identify and kill the tumor cells (CD19+ cells)” NCT05613348 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT05613348 ↗ |